Kristina R Patterson1, Josep Dalmau1,2,3, Eric Lancaster1. 1. Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA. 2. Hospital Clinic-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain. 3. Catalan Institution for Research and Advanced Studies Barcelona, Spain.
Abstract
OBJECTIVE: To determine the pathogenic mechanisms of autoantibodies to the cell adhesion molecule Caspr2 in acquired neuromyotonia and autoimmune encephalitis. METHODS: Caspr2-positive samples were confirmed using a cell-based assay, and their IgG subtypes were determined by enzyme-linked immunosorbent assay and cell-based assay. A solid phase binding assay quantified the binding of Caspr2 to contactin-2 in the presence of Caspr2 autoantibodies. Living cultures of primary rat hippocampal neurons were incubated with Caspr2-positive or control sera, and the distribution of Caspr2-positive immunofluorescent puncta and total surface Caspr2 was quantified. HEK cells transfected to express Caspr2 were incubated with Caspr2-positive or control samples, and cell-surface biotinylation and Western blot were used to assess total, internalized, and surface levels of Caspr2. RESULTS: We confirmed 6 samples with strong Caspr2 reactivity. IgG4 Caspr2 antibodies were present in all 6 cases. Caspr2 interacted with another cell adhesion molecule, contactin-2, with nanomolar affinity in the solid phase assay, and Caspr2 autoantibodies inhibited this interaction. Caspr2 autoantibodies did not affect the surface expression of Caspr2 in rat primary hippocampal neurons or transfected HEK cells. INTERPRETATION: Caspr2 autoantibodies inhibit the interaction of Caspr2 with contactin-2 but do not cause internalization of Caspr2. Functional blocking of cell adhesion molecule interactions represents a potential mechanism with therapeutic implications for IgG4 autoantibodies to cell adhesion molecules in neurological diseases. Ann Neurol 2018;83:40-51.
OBJECTIVE: To determine the pathogenic mechanisms of autoantibodies to the cell adhesion molecule Caspr2 in acquired neuromyotonia and autoimmune encephalitis. METHODS:Caspr2-positive samples were confirmed using a cell-based assay, and their IgG subtypes were determined by enzyme-linked immunosorbent assay and cell-based assay. A solid phase binding assay quantified the binding of Caspr2 to contactin-2 in the presence of Caspr2 autoantibodies. Living cultures of primary rat hippocampal neurons were incubated with Caspr2-positive or control sera, and the distribution of Caspr2-positive immunofluorescent puncta and total surface Caspr2 was quantified. HEK cells transfected to express Caspr2 were incubated with Caspr2-positive or control samples, and cell-surface biotinylation and Western blot were used to assess total, internalized, and surface levels of Caspr2. RESULTS: We confirmed 6 samples with strong Caspr2 reactivity. IgG4 Caspr2 antibodies were present in all 6 cases. Caspr2 interacted with another cell adhesion molecule, contactin-2, with nanomolar affinity in the solid phase assay, and Caspr2 autoantibodies inhibited this interaction. Caspr2 autoantibodies did not affect the surface expression of Caspr2 in rat primary hippocampal neurons or transfected HEK cells. INTERPRETATION:Caspr2 autoantibodies inhibit the interaction of Caspr2 with contactin-2 but do not cause internalization of Caspr2. Functional blocking of cell adhesion molecule interactions represents a potential mechanism with therapeutic implications for IgG4 autoantibodies to cell adhesion molecules in neurological diseases. Ann Neurol 2018;83:40-51.
Authors: S Poliak; L Gollan; R Martinez; A Custer; S Einheber; J L Salzer; J S Trimmer; P Shrager; E Peles Journal: Neuron Date: 1999-12 Impact factor: 17.173
Authors: Yael Eshed; Konstantin Feinberg; Sebastian Poliak; Helena Sabanay; Offra Sarig-Nadir; Ivo Spiegel; John R Bermingham; Elior Peles Journal: Neuron Date: 2005-07-21 Impact factor: 17.173
Authors: Maartje G Huijbers; Wei Zhang; Rinse Klooster; Erik H Niks; Matthew B Friese; Kirsten R Straasheijm; Peter E Thijssen; Hans Vrolijk; Jaap J Plomp; Pauline Vogels; Mario Losen; Silvère M Van der Maarel; Steven J Burden; Jan J Verschuuren Journal: Proc Natl Acad Sci U S A Date: 2013-12-02 Impact factor: 11.205
Authors: Judy King Man Ng; Joachim Malotka; Naoto Kawakami; Tobias Derfuss; Mohsen Khademi; Tomas Olsson; Christopher Linington; Masaaki Odaka; Björn Tackenberg; Harald Prüss; Jan M Schwab; Lutz Harms; Hendrik Harms; Claudia Sommer; Matthew N Rasband; Yael Eshed-Eisenbach; Elior Peles; Reinhard Hohlfeld; Nobuhiro Yuki; Klaus Dornmair; Edgar Meinl Journal: Neurology Date: 2012-10-24 Impact factor: 9.910
Authors: Agnes van Sonderen; Helena Ariño; Mar Petit-Pedrol; Frank Leypoldt; Peter Körtvélyessy; Klaus-Peter Wandinger; Eric Lancaster; Paul W Wirtz; Marco W J Schreurs; Peter A E Sillevis Smitt; Francesc Graus; Josep Dalmau; Maarten J Titulaer Journal: Neurology Date: 2016-07-01 Impact factor: 9.910
Authors: Christian S Rosenow; Sara Dawit; Luca P Farrugia; Katharine A Henry Ma; Akanksha Sharma; Andrew McKeon; Alyx B Porter; Marie F Grill Journal: Neurohospitalist Date: 2021-05-07
Authors: Bo Sun; Melanie Ramberger; Kevin C O'Connor; Rachael J M Bashford-Rogers; Sarosh R Irani Journal: Nat Rev Neurol Date: 2020-07-28 Impact factor: 44.711
Authors: Stefan Macher; Friedrich Zimprich; Desiree De Simoni; Romana Höftberger; Paulus S Rommer Journal: Front Immunol Date: 2018-11-22 Impact factor: 7.561
Authors: Gabriela Dumitrita Stanciu; Veronica Bild; Daniela Carmen Ababei; Razvan Nicolae Rusu; Sorin Ioan Beschea Chiriac; Elena Rezuş; Andrei Luca Journal: Int J Mol Sci Date: 2019-09-13 Impact factor: 5.923